Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02688530 · ClinicalTrials.gov registry record · Phase 4
Intravenous Dexamethasone on Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT02688530: Completed Phase 4 study, sponsored by Hospital for Special Surgery, New York.
NCT02688530 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 140 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02688530, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
Previous studies have confirmed that IV dexamethasone prolongs brachial plexus blocks. However, these studies only used fixed doses of IV dexamethasone at relatively high doses, which could potentially lead to increased glucose levels, delayed wound healing, and unintended side effects. There remains a paucity of research on the effective dose range of IV dexamethasone for the prolongation of supraclavicular blocks. The optimal dosage of IV dexamethasone for prolongation of analgesia vs. motor block prolongation from supraclavicular blocks in shoulder surgery has yet to be delineated.
Primary Outcome
Defined as time from block placement until "pain relief from the block completely wears off" in the operative shoulder.
Interventions
- DRUG IV Saline
- DRUG IV Dexamethasone 4mg
- DRUG IV Dexamethasone 6mg
- DRUG IV Dexamethasone 8mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-11-19 |
| Phase | Phase 4 |
What the finished NCT02688530 record still lists
NCT02688530 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 4 interventions - of which IV Saline is the first listed.
NCT02688530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02688530 about?
NCT02688530 is a clinical study titled "Intravenous Dexamethasone on Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy". Previous studies have confirmed that IV dexamethasone prolongs brachial plexus blocks. However, these studies only used fixed doses of IV dexamethasone at relatively high doses, which could potentially lead to increased glucose levels, delayed wound healing, and unintended side effects. There remain...
What is the current status of trial NCT02688530?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2016-05. Estimated completion is 2017-11-19.
What interventions are being tested in trial NCT02688530?
The interventions under investigation include: IV Saline (DRUG), IV Dexamethasone 4mg (DRUG), IV Dexamethasone 6mg (DRUG), IV Dexamethasone 8mg (DRUG).
Who is sponsoring clinical trial NCT02688530?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02688530's enrollment target sits among peer trials
140 581st of 2000 higher than 1,408 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia